Back to top
more

AnaptysBio (ANAB)

(Delayed Data from NSDQ)

$26.58 USD

26.58
332,065

+0.24 (0.91%)

Updated May 3, 2024 04:00 PM ET

After-Market: $26.59 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

by Zacks Equity Research

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

by Zacks Equity Research

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors

by Zacks Equity Research

The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

by Zacks Equity Research

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD

by Zacks Equity Research

Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.

    Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why

    by Zacks Equity Research

    Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.

    Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug

    by Zacks Equity Research

    The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

    Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies

    by Zacks Equity Research

    Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.

    Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion

    by Zacks Equity Research

    Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.

    Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics

    by Zacks Equity Research

    Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.

    AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 67.57% and 150.54%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication

    by Zacks Equity Research

    The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.

    AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Glaxo (GSK) Gets FDA Nod for Endometrial Cancer Drug Jemperli

    by Zacks Equity Research

    The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating women with recurrent or advanced dMMR endometrial cancer.

    AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure

    by Zacks Equity Research

    AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.

    AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: Should You Buy?

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    AnaptysBio (ANAB) Jumps: Stock Rises 7.7%

    by Zacks Equity Research

    AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

    AnaptysBio Shares Up on Positive Top-Line Psoriasis Data

    by Zacks Equity Research

    AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.

    AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    AnaptysBio, Inc. (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (ANAB) Outperforming Other Medical Stocks This Year?

    Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (ANAB) Outperforming Other Medical Stocks This Year?